The ACTIV-3 phase III study testing Eli Lilly and Co.’s COVID-19 antibody candidate, LY-CoV555, which was paused two weeks ago following a participant’s unexplained illness, has now been halted, the company reported Oct. 26.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aerpio, Alligator, Alzheon, Amgen, Bridgebio, Catabasis, Eisai, Ellodi, Genetx, Iveena, Lilly, Novavax, Olatec, Oncolytics, Pfizer, Phoenix Tissue Repair, Prilenia, Rafael, Reata, Scholar Rock, Sumitomo Dainippon, Syntrix, Takeda, Transgene, Ultragenyx.

Interest in testing the mettle of three widely available drugs against COVID-19 gained traction Monday, led by suggestions that daily low-dose aspirin might lower the risks of complications and death from the disease.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Advaxis, Allakos, Allergy, Amarin, Ana, Arcutis, Atyr, Biocardia, Biophytis, Biosig, Cingulate, Crinetics, Exelixis, Forma, Galera, Glycomimetics, Gmax, Hifibio, Kiniksa, Mustang, Nanobiotix, NBE, Novartis, PTC, Regeneron, Rexgenero, Sanofi, VBI.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aldeyra, Akebia, Allakos, Aurinia, Bayer, Biondvax, Boehringer, Goldfinch, Immutep, Innate, Lilly, Phasebio, Phosplatin, Sumitomo.

The Chinatrials roundtable went virtual this year and drew clinical trial experts to discuss state-of-the-art clinical trial design strategies, which are increasingly important in a more competitive clinical landscape.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alnylam, Ardelyx, Aslan, Daiichi, Dicerna, Enlivex, Fibrogen, Galera, Genmab, Horizon, Immunitybio, Medicinova, Mesoblast, Moderna, Nantkwest, Omeros, Soligenix, Trippbio.

Crispr Therapeutics AG's first stab at developing an allogeneic CAR T-cell therapy, CTX-110, looks promising, but the efficacy data were overshadowed by a death in the study.

PERTH, Australia – Sydney-based Actinogen Medical Ltd. will advance its lead compound, Xanamem, into two proof-of-concept phase II studies in Alzheimer’s disease and fragile X syndrome.